ArticleFrontiers in pharmacology2021

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma.

Yaohua Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.